Rheumatoid Factor 360 Tests

Apolipoprotein A1 243 Tests

GFAP Reagent Kit 100 Tests

GFAP Reagent Kit 200 Tests

UCH-L1 Reagent Kit 100 Tests

UCH-L1 Reagent Kit 200 Tests

IgE Reagent Kit 200 tests

i-STAT TBI cartridge

NMP22 BladderChek Test is an in vitro immunoassay intended for the qualitative detection of the nuclear mitotic apparatus protein (NuMA) in urine of persons with risk factors or symptoms of bladder cancer or with a history of bladder cancer.

NMP22 BladderChek Control Kit consists of a Negative and a Positive Control solution for use as an external control for the NMP22 BladderChek Test.

Molecular Urine Transport Kit 96EA

Kit Vaginal Reagent COR IVD

Anti-SS-B ELISA is a test system for the quantitative measurement of IgG class autoantibodies against SS-B (La) in human serum or plasma.

Tempo Refill Kit - This is a convenience kit which contains multiple devices with different counts: Lancets/Strips/BD needles and gauze pads.

The Local Run Manager CF Clinical Sequencing analysis module is for use with Illumina MiSeqDx Cystic Fibrosis Clinical Sequencing Assay. The assay detects mutations in the protein coding regions and intron/exon boundaries of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, including two large deletions and two-deep intronic mutations. The analysis module performs secondary analysis and report generation from sequencing runs that use the MiSeqDx Cystic Fibrosis Clinical Sequencing Assay.

The Local Run Manager CF 139 Variant analysis module is for use with Illumina MiSeqDx Cystic Fibrosis 139-Variant Assay. The assay detects 139 clinically relevant cystic fibrosis disease-causing mutations and variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in genomic DNA isolated from human peripheral whole blood specimens. The analysis module performs secondary analysis and report generation from sequencing runs that use the MiSeqDx Cystic Fibrosis 139-Variant Assay.

The Local Run Manager CF Clinical Seq 2.0 Micro analysis module is for use with TruSight Cystic Fibrosis Clinical Sequencing Assay when processing 24–36 samples. The assay detects mutations in the protein coding regions and intron/exon boundaries of the cystic fibrosis transmembrane conductance regulator (CFTR) gene, including two large deletions and two-deep intronic mutations. The analysis module performs secondary analysis and report generation from sequencing runs that use TruSight Cystic Fibrosis.

The Local Run Manager CF 139-Variant 2.0 Micro analysis module is for use with TruSight Cystic Fibrosis 139-Variant Assay when processing 24–36 samples. The assay detects 139 clinically relevant cystic fibrosis disease-causing mutations and variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in genomic DNA isolated from human peripheral whole blood specimens. The analysis module performs secondary analysis and report generation from sequencing runs that use TruSight Cystic Fibrosis. For more information on TruSight Cystic Fibrosis.

ID Plates, Single Series, Cleargel

4-Series Cleargel ID Plates, Small Well

ID Plates, 4 Series, Agarose

ID Plates, 4 Series, Cleargel (Large Well)

Atellica CH Prealbumin (PALB)

Atellica CH C-Reactive Protein (RCRP) Reagent

Atellica CH High Sensitivity C-Reactive Protein (hCRP2) Reagent

Haptoglobin (HAPT2) Atellica CH

Quantitative determination of plasminogen activity as an aid in the diagnosis and monitoring of fibrinolytic disorders

Establishment of reference curves for the determination of free light chains (FLC) type kappa and type lambda on BN Systems.

Assayed accuracy and precision controls in the determination of free light chains (FLC) type kappa and type lambda on BN Systems.

Assayed accuracy and precision controls in the determination of free light chains (FLC) type kappa and type lambda on BN Systems.